Gladius Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,925
| Closed | -$844K | – | 32 |
|
|
2026
Q1 | $854K | Sell |
3,925
-3,647
| -48% | -$809K | 0.04% | 96 |
|
|
2025
Q4 | $1.73M | Buy |
+7,572
| New | +$1.72M | 0.09% | 80 |
|
|
2025
Q3 | – | Sell |
-1,173
| Closed | -$239K | – | 103 |
|
|
2025
Q2 | $218K | Sell |
1,173
-4,294
| -79% | -$798K | 0.08% | 61 |
|
|
2025
Q1 | $1.15M | Sell |
5,467
-3,590
| -40% | -$698K | 0.3% | 56 |
|
|
2024
Q4 | $1.61M | Buy |
9,057
+2,667
| +42% | +$490K | 0.17% | 62 |
|
|
2024
Q3 | $1.26M | Buy |
6,390
+2,149
| +51% | +$401K | 0.15% | 65 |
|
|
2024
Q2 | $727K | Buy |
4,241
+1,798
| +74% | +$298K | 0.09% | 92 |
|
|
2024
Q1 | $445K | Buy |
+2,443
| New | +$421K | 0.15% | 103 |
|
|
2023
Q4 | – | Sell |
-8,844
| Closed | -$1.29M | – | 313 |
|
|
2023
Q3 | $1.32M | Buy |
8,844
+3,455
| +64% | +$507K | 0.06% | 115 |
|
|
2023
Q2 | $726K | Buy |
5,389
+3,632
| +207% | +$533K | 0.04% | 110 |
|
|
2023
Q1 | $280K | Sell |
1,757
-953
| -35% | -$146K | 0.02% | 142 |
|
|
2022
Q4 | $438K | Sell |
2,710
-6,357
| -70% | -$975K | 0.03% | 107 |
|
|
2022
Q3 | $1.22M | Buy |
9,067
+7,374
| +436% | +$1.06M | 0.05% | 102 |
|
|
2022
Q2 | $260K | Sell |
1,693
-5,325
| -76% | -$814K | 0.01% | 152 |
|
|
2022
Q1 | $1.14M | Buy |
7,018
+5,280
| +304% | +$767K | 0.08% | 61 |
|
|
2021
Q4 | $236K | Buy |
1,738
+1,001
| +136% | +$118K | 0.02% | 170 |
|
|
2021
Q3 | $80K | Buy |
737
+302
| +69% | +$34.5K | 0.01% | 109 |
|
|
2021
Q2 | $49K | Buy |
+435
| New | +$49K | ﹤0.01% | 117 |
|
|
2020
Q4 | – | Sell |
-3,104
| Closed | -$298K | – | 164 |
|
|
2020
Q3 | $272K | Buy |
+3,104
| New | +$292K | 0.03% | 156 |
|
|
2020
Q1 | – | Sell |
-426
| Closed | -$38K | – | 126 |
|
|
2019
Q4 | $38K | Sell |
426
-5,485
| -93% | -$455K | ﹤0.01% | 158 |
|
|
2019
Q3 | $448K | Sell |
5,911
-349
| -6% | -$23.9K | 0.02% | 181 |
|
|
2019
Q2 | $460K | Sell |
6,260
-19,882
| -76% | -$1.56M | 0.03% | 135 |
|
|
2019
Q1 | $2.11M | Sell |
26,142
-1,294
| -5% | -$106K | 0.12% | 86 |
|
|
2018
Q4 | $2.53M | Buy |
27,436
+24,291
| +772% | +$2.14M | 0.12% | 81 |
|
|
2018
Q3 | $297K | Sell |
3,145
-4,567
| -59% | -$433K | 0.03% | 64 |
|
|
2018
Q2 | $715K | Buy |
+7,712
| New | +$753K | 0.07% | 60 |
|
Other funds holding ABBV
Gladius Capital Management's ABBV Position: Q2 2026 in Review
Gladius Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 3,925 shares — an estimated $844K sold.
Gladius Capital Management first reported a position in ABBV in Q2 2018 and held it in 26 quarters. The position peaked at $2.53M in Q4 2018. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Gladius Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
- Gladius Capital Management sold 3,925 AbbVie shares in Q2 2026, an estimated $844K.
- Gladius Capital Management first reported a position in AbbVie in Q2 2018 and held it in 26 quarters.
- Gladius Capital Management's AbbVie position peaked at $2.53M in Q4 2018.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Gladius Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.